Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alaunos Therapeutics (TCRT – Research Report), Anixa Biosciences (ANIX – Research Report) and Autolus Therapeutics (AUTL – Research Report).
Alaunos Therapeutics (TCRT)
In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Hold rating on Alaunos Therapeutics. The company’s shares closed last Wednesday at $0.66, close to its 52-week low of $0.61.
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of
Alaunos Therapeutics has an analyst consensus of Hold.
See today’s best-performing stocks on TipRanks >>
Anixa Biosciences (ANIX)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Anixa Biosciences today and set a price target of $11.00. The company’s shares closed last Wednesday at $2.82, close to its 52-week low of $2.30.
According to TipRanks.com, Chen is a 3-star analyst with an average return of
Currently, the analyst consensus on Anixa Biosciences is a Moderate Buy with an average price target of $11.00.
Autolus Therapeutics (AUTL)
In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Autolus Therapeutics, with a price target of $11.00. The company’s shares closed last Wednesday at $4.23.
According to TipRanks.com, Burns is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Autolus Therapeutics with a $14.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TCRT:
- Wall Street Analysts Are Bullish on Top Technology Picks
- Digihost Technology (DGHI) Receives a Buy from H.C. Wainwright
- Beam Global (BEEM) Gets a Hold Rating from H.C. Wainwright
- H.C. Wainwright Sticks to Their Buy Rating for American Resources (AREC)
- Wedbush Sticks to Its Buy Rating for Axcella Health (AXLA)